Draig Therapeutics DT-101 Phase 1 data put MEG biomarkers at the centre of depression trials
DT-101 may revive AMPA receptor depression research, but Phase 2 must prove safety signals can become real clinical benefit.
DT-101 may revive AMPA receptor depression research, but Phase 2 must prove safety signals can become real clinical benefit.